O Pagani
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E, Burstein H, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2018; 29:2153.
01.10.2018De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
01.10.2018Ann Oncol 2018; 29:2153
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E P, Burstein H J, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S Y, Curigliano G
A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
Gennari A, Bernhard J, Morales S, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub U, Colleoni M, Kennedy M, von Moos R, Cortes J, Vidal M, Hennessy B, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Ann Oncol 2017
08.12.2017A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
08.12.2017Ann Oncol 2017
Gennari A, Bernhard J, Morales S Murillo, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub Ursula, Colleoni M, Kennedy M J, von Moos R, Cortes J, Vidal M J, Hennessy B, Jerusalem G
Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Bonnefoi H, Curigliano G. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. Ann Oncol 2017
25.09.2017Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
25.09.2017Ann Oncol 2017
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson Per, Jiang Z, Jassem J, Khaled H, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E P, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S Y, Bonnefoi H, Curigliano G
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
Regan M, Goldhirsch A, Coates A, Gelber R, Abdi E, Ruhstaller T, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H, Láng I, Fleming G, Francis P, Walley B, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 2017; 28:2225-2232.
01.09.2017Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
01.09.2017Ann Oncol 2017; 28:2225-2232
Regan M M, Goldhirsch A, Coates A S, Gelber R D, Abdi E A, Ruhstaller Thomas, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H L, Láng I, Fleming G F, Francis P A, Walley B A, Pagani O
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28:1700-1712.
01.08.2017De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
01.08.2017Ann Oncol 2017; 28:1700-1712
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016
19.12.2016Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
19.12.2016Ann Oncol 2016
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann Beat, Moos R von, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller Thomas, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess Dagmar, Mamot C
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Phillips K, Aldridge J, International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012; 106:1618-25.
24.04.2012Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
24.04.2012Br J Cancer 2012; 106:1618-25
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R D, Price K N, Goldhirsch A, Coates A S, Pagani O, Cardoso F, Thürlimann Beat, Harvey V, Thompson A, Phillips K-A, Aldridge J, International Breast Cancer Study Group
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
Zaman K, Aebi S, Brauchli P, Genton C, Berthod G, Giobbie-Hurder A, Simcock M, Lüthi J, Pagani O, Schonenberger A, Huober J, Thürlimann B, on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol 2011
14.10.2011Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
14.10.2011Ann Oncol 2011
Zaman K, Aebi S, Brauchli P, Genton C, Berthod G, Giobbie-Hurder A, Simcock M, Lüthi J, Pagani O, Schonenberger A, Huober Jens, Thürlimann Beat, on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 2011; 18:257-64.
09.03.2011Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
09.03.2011Endocr Relat Cancer 2011; 18:257-64
Köberle Dieter, Thürlimann Beat, Pilop C, Crowe S, Öhlschlegel Christian, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Regan M, SOFT/TEXT/PERCHE Steering Committee, Gelber R, Goldhirsch A, Coates A, Castiglione-Gertsch M, Maibach R, Thürlimann B, Price K, Fleming G, Francis P, Perez E, Torrisi R, Walley B, Pagani O, International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 2008; 19:1231-41.
01.07.2008Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
01.07.2008Ann Oncol 2008; 19:1231-41
Regan M M, SOFT/TEXT/PERCHE Steering Committee, Gelber R D, Goldhirsch A, Coates A S, Castiglione-Gertsch M, Maibach R, Thürlimann Beat, Price K N, Fleming G F, Francis P, Perez E A, Torrisi R, Walley B, Pagani O, International Breast Cancer Study Group
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
Keshaviah A, Coates A, Gelber R, Castiglione Gertsch M, Simoncini E, Pagani O, Price K, Aebi S, Mendiola C, Thürlimann B, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007; 18:701-8.
01.04.2007CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
01.04.2007Ann Oncol 2007; 18:701-8
Keshaviah A, Coates A S, Gelber R D, Castiglione Gertsch M, Simoncini E, Pagani O, Price K N, Aebi S, Mendiola C, Thürlimann Beat, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)
Hess D, Ribi K, Ballabeni P, Schuller J, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann B, Köberle D, Swiss Group for Clinical Cancer Research. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology 2007; 73:228-37.
01.01.2007Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)
01.01.2007Oncology 2007; 73:228-37
Hess Dagmar, Ribi K, Ballabeni P, Schuller J C, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann Beat, Köberle Dieter, Swiss Group for Clinical Cancer Research
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
Pagani O, Longhi S, Ruggeri M, Graffeo R, Hess D, Thürlimann B, Lombardi D, Crivellari D, Munzone E, Nolé F, Sessa C, Goldhirsch A. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. Ann Oncol 2005; 16:1609-17.
01.10.2005Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
01.10.2005Ann Oncol 2005; 16:1609-17
Pagani O, Longhi S, Ruggeri M, Graffeo R, Hess D, Thürlimann Beat, Lombardi D, Crivellari D, Munzone E, Nolé F, Sessa C, Goldhirsch A
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
Colleoni M, Veronesi A, Holmberg S, Erzen D, Forbes J, Murray E, Thürlimann B, Simoncini E, Pagani O, Collins J, Crivellari D, Rudenstam C, Lindtner J, Price K, Castiglione-Gertsch M, Coates A, Gelber R, Li S, Goldhirsch A. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005; 16:716-25.
01.05.2005Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
01.05.2005Ann Oncol 2005; 16:716-25
Colleoni M, Veronesi A, Holmberg S, Erzen D, Forbes J, Murray E, Thürlimann Beat, Simoncini E, Pagani O, Collins J, Crivellari D, Rudenstam C-M, Lindtner J, Price K N, Castiglione-Gertsch M, Coates A S, Gelber R D, Li S, Goldhirsch A
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Hess D, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann B, Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5.
01.12.2004Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
01.12.2004Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5
Hess Dagmar, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann Beat, Swiss Group of Clinical Cancer Research (SAKK)
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6.
01.03.2001High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
01.03.2001Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91.
01.08.2000Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
01.08.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess D, Thürlimann B, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45.
01.05.1999Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
01.05.1999Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A
Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial
Stupp R, Giroux B, Schläpfer J, Sarkany M, Bastian G, Sessa C, Cerny T, Gerard B, Pagani O, Bauer J, Leyvraz S. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1233-42.
01.11.1998Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial
01.11.1998Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1233-42
Stupp R, Giroux B, Schläpfer J, Sarkany M, Bastian G, Sessa C, Cerny Thomas, Gerard B, Pagani O, Bauer J, Leyvraz S
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI
Pagani O, Price K, Fey M, Simoncini E, Thürlimann B, Cavalli F, Coates A, Crivellari D, Collins J, Lindtner J, Rudenstam C, Goldhirsch A, Gelber R, Castiglione M, O'Neill A, Senn H. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. European journal of cancer (Oxford, England : 1990) 1998; 34:632-40.
01.04.1998Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI
01.04.1998European journal of cancer (Oxford, England : 1990) 1998; 34:632-40
Pagani O, Price K, Fey M, Simoncini E, Thürlimann Beat, Cavalli F, Coates A, Crivellari D, Collins J, Lindtner J, Rudenstam C M, Goldhirsch A, Gelber R D, Castiglione M, O'Neill A, Senn H J